Database Resources

Here we provide information about and links to external databases that can be used for cancer research

SEER

SEER Data & Software

SEER Incidence Data
  • Description  
    • The Surveillance, Epidemiology, and End Results (SEER) Program provides information on cancer statistics in an effort to reduce the cancer burden among the U.S. population. SEER is supported by the Surveillance Research Program (SRP) in NCI’s Division of Cancer Control and Population Sciences (DCCPS).
    • Link to website: Surveillance, Epidemiology, and End Results Program (cancer.gov) 
  • Training 
  • Example publications using SEER data: 
    • Mourad, M., Jetmore, T., Jategaonkar, A. A., Moubayed, S., Moshier, E., & Urken, M. L. (2017). Epidemiological Trends of Head and Neck Cancer in the United States: A SEER Population Study. Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 75(12), 2562–2572. https://doi.org/10.1016/j.joms.2017.05.008 
    • Tsao, C. K., Small, A. C., Kates, M., Moshier, E. L., Wisnivesky, J. P., Gartrell, B. A., Sonpavde, G., Godbold, J. H., Palese, M. A., Hall, S. J., Oh, W. K., & Galsky, M. D. (2013). Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World journal of urology, 31(6), 1535–1539. https://doi.org/10.1007/s00345-012-1001-3 

 

https://seer.cancer.gov/data/

 

SEER Statistical Software
  • SEER*Explorer can be used to view cancer statistics from SEER data by race, age, gender, stage, and cancer subtypes, covering 48% of the U.S. population. 
SEER-Medicare Linked Database
  • Description  
    • SEER-Medicare data is the linkage between the SEER cancer registry and Medicare claims data. The linkage of these two data sources results in a unique population-based source of information. 
    • Link to website: SEER-Medicare Linked Data Resource (cancer.gov)  
    • Use requires an application, data use agreement, and fees  
  • Analytic Support 
  • Example publications using SEER-Medicare data: 
    • Taioli, E., Wolf, A., Alpert, N., Rosenthal, D., & Flores, R. (2023). Malignant pleural mesothelioma characteristics and outcomes: A SEER-Medicare analysis. Journal of surgical oncology, 128(1), 134–141. https://doi.org/10.1002/jso.27243 
    • Wolf, A., Alpert, N., Tran, B. V., Liu, B., Flores, R., & Taioli, E. (2019). Persistence of racial disparities in early-stage lung cancer treatment. The Journal of thoracic and cardiovascular surgery, 157(4), 1670–1679.e4. https://doi.org/10.1016/j.jtcvs.2018.11.108 
  •  
SEER-Medicare Health Outcomes Survey (MHOS) Linked Database
  • Description 
  • Accessing the data 
  • Example Publications using MHOS 
    • Park, J., Kent, E. E., Lund, J. L., Anderson, C., Olshan, A. F., Brewster, W. R., & Nichols, H. B. (2023). Adjuvant radiation therapy and health-related quality of life among older women with early-stage endometrial cancer: an analysis using the SEER-MHOS linkage. Cancer causes & control : CCC34(3), 223–231. https://doi.org/10.1007/s10552-022-01658-8 
    • Park, C., Park, S. K., Woo, A., & Ng, B. P. (2022). Health-related quality of life among elderly breast cancer patients treated with adjuvant endocrine therapy: a U.S Medicare population-based study. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation31(5), 1345–1357. https://doi.org/10.1007/s11136-021-03059-x 
SEER-Consumer Assessment of Healthcare Providers and Systems (SEER-CAHPS) Linked Data Resource
  • Description 
  • Accessing Data 
  • Example Publications using SEER-CAHPS
    • Pandit, A. A., Gressler, L. E., Halpern, M. T., Kamel, M., Payakachat, N., & Li, C. (2022). Racial/Ethnic Disparities in Patient Care Experiences among Prostate Cancer Survivors: A SEER-CAHPS Study. Current oncology (Toronto, Ont.)29(11), 8357–8373. https://doi.org/10.3390/curroncol29110659 
    • Lines, L. M., Cohen, J., Kirschner, J., Barch, D. H., Halpern, M. T., Kent, E. E., Mollica, M. A., & Smith, A. W. (2022). Associations between illness burden and care experiences among Medicare beneficiaries before or after a cancer diagnosis. Journal of geriatric oncology13(5), 731–737. https://doi.org/10.1016/j.jgo.2022.02.017 
SEER-Medicaid Linked Data Resource
  • Example Publications using SEER-Medicaid 
    • Ganga, A., Kim, E. J., Lee, J. Y., Leary, O. P., Sastry, R. A., Fridley, J. S., Chang, K. E., Niu, T., Sullivan, P. Z., Somasundar, P. S., & Gokaslan, Z. L. (2023). Disparities in primary spinal osseous malignant bone tumor survival by Medicaid-status: a national population-based risk analysis. World neurosurgery, S1878-8750(23)01371-2. Advance online publication. https://doi.org/10.1016/j.wneu.2023.09.103 
    • Wang, S., & Ge, C. (2023). High risk of non-cancer mortality in bladder cancer patients: evidence from SEER-Medicaid. Journal of cancer research and clinical oncology149(12), 10203–10215. https://doi.org/10.1007/s00432-023-04867-z 
National Cancer Database (NCDB)
  • Description
  • Example publications using NCDB data: 
    • Galsky, M. D., Diefenbach, M., Mohamed, N., Baker, C., Pokhriya, S., Rogers, J., Atreja, A., Hu, L., Tsao, C. K., Sfakianos, J., Mehrazin, R., Waingankar, N., Oh, W. K., Mazumdar, M., & Ferket, B. S. (2017). Web-Based Tool to Facilitate Shared Decision Making With Regard to Neoadjuvant Chemotherapy Use in Muscle-Invasive Bladder Cancer. JCO clinical cancer informatics, 1, 1–12. https://doi.org/10.1200/CCI.17.00116 
    • Zeidman, M., Alberty-Oller, J. J., Ru, M., Pisapati, K. V., Moshier, E., Ahn, S., Mazumdar, M., Port, E., & Schmidt, H. (2020). Use of neoadjuvant versus adjuvant chemotherapy for hormone receptor-positive breast cancer: a National Cancer Database (NCDB) study. Breast cancer research and treatment, 184(1), 203–212. https://doi.org/10.1007/s10549-020-05809-w 
    • Galsky, M. D., Stensland, K. D., Moshier, E., Sfakianos, J. P., McBride, R. B., Tsao, C. K., Casey, M., Boffetta, P., Oh, W. K., Mazumdar, M., & Wisnivesky, J. P. (2016). Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology34(8), 825–832. https://doi.org/10.1200/JCO.2015.64.1076
    • Galsky, M. D., Stensland, K., Sfakianos, J. P., Mehrazin, R., Diefenbach, M., Mohamed, N., Tsao, C. K., Boffetta, P., Wiklund, P., Oh, W. K., Mazumdar, M., & Ferket, B. (2016). Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement. Journal of clinical oncology : official journal of the American Society of Clinical Oncology34(22), 2627–2635. https://doi.org/10.1200/JCO.2016.67.503
  •  
  •  
National Program of Cancer Registries (NPCR)
  • Description
  • Publications using NPCR data:
    • Benard, V. B., Greek, A., Jackson, J. E., Senkomago, V., Hsieh, M. C., Crosbie, A., Alverson, G., Stroup, A. M., Richardson, L. C., & Thomas, C. C. (2019). Overview of Centers for Disease Control and Prevention’s Case Investigation of Cervical Cancer Study. Journal of women’s health (2002)28(7), 890–896. https://doi.org/10.1089/jwh.2019.7849
North American Association of Central Cancer Registries (NAACCR)

 

 

New York State Cancer Registry
Prospective Registry for Myeloid Mutations

Other Data Resources

MarketScan

MarketScan 

  • Description 
    • From IBM: The IBM® MarketScan® Research Databases are a family of research data sets that integrate de-identified patient-level health data (medical, drug and dental), productivity (workplace absence, short- and long-term disability and workers’ compensation), laboratory results, health risk assessments (HRAs), hospital discharges and electronic medical records (EMRs) into data sets available for healthcare research. Data are contributed by large employers, managed care organizations, hospitals, EMR providers, Medicare and Medicaid. 
  • Link to website: IBM MarketScan Research Databases for Life Sciences Researchers  
  • Data Ark description of IBM® MarketScan®: IBM Market Scan | Scientific Computing and Data (mssm.edu) 
  • Example publications using MarketScan data: 
    • Blank, L. J., Agarwal, P., Kwon, C. S., & Jetté, N. (2023). Association of first anti-seizure medication choice with injuries in older adults with newly diagnosed epilepsy. Seizure, 109, 20–25. https://doi.org/10.1016/j.seizure.2023.05.0060 
  •  
PROSPR
  • Description 
  • Accessing 
    • PROSPR DataShare (PDS)
    • Use PROSPR DataShare
      • Public use data sets
        • HIPPA-defined de-identified data sets available to any requestor who agrees to data use conditions
        • Turnaround time of about 2 weeks.
      • Restricted use data sets
        • Custom HIPAA-defined limited data sets
        • Generally requires collaboration with PROSPR investigators
        • 2-step review process
          • Submit an inquiry
          • If approved, submit a full proposal
        • Cost depends on involvement of PROSPR investigators/staff
        • Timeline
          • Review typically takes about three to four months
          • Data set delivery typically takes 1-2 months.
  • Example publications using PROSPR: 
    • Burnett-Hartman, A. N., Carroll, N. M., Honda, S. A., Joyce, C., Mitra, N., Neslund-Dudas, C., Olaiya, O., Rendle, K. A., Schnall, M. D., Vachani, A., & Ritzwoller, D. P. (2022). Community-based Lung Cancer Screening Results in Relation to Patient and Radiologist Characteristics: The PROSPR Consortium. Annals of the American Thoracic Society19(3), 433–441. https://doi.org/10.1513/AnnalsATS.202011-1413OC
    • Ritzwoller, D. P., Meza, R., Carroll, N. M., Blum-Barnett, E., Burnett-Hartman, A. N., Greenlee, R. T., Honda, S. A., Neslund-Dudas, C., Rendle, K. A., & Vachani, A. (2021). Evaluation of Population-Level Changes Associated With the 2021 US Preventive Services Task Force Lung Cancer Screening Recommendations in Community-Based Health Care Systems. JAMA network open4(10), e2128176. https://doi.org/10.1001/jamanetworkopen.2021.28176
DREAM EMR Data
MGB-EMR Data
  • Description
      • Linked the electronic health records from all Mass General Brigham facilities with multiple long-term outcome and health care utilization data, including insurance claims data, National Death Index (through Centers for Medicare & Medicaid Services), and state death data. 
Additional Data Sources

NCI Cancer Research Data Commons (CRDC)

NIH Resources for Researchers Search

NIH Cancer Data Access System (“CDAS”) 

From NIH: